KIF11 and plasma cell myeloma: For example, filanesib (Arry-520), a KIF11 inhibitor, is validated as a promising agent in phase II clinical trials of multiple myeloma, which is effective in both monotherapy and combination therapy with proteasome inhibitors (Hansson et al. 2020; Hernández-García et al. 2017; Algarín et al. 2020).